An Early Phase 1 interventional study of Ketamine infusion and Lidocaine Intravenous Infusion in Refractory Chronic Migraine, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-04-20.
Sponsored by Assiut University · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing lidocaine in Migraine Disorders — 5 open to participants now, 5 under way, none of them phase 3. Lidocaine · Migraine Disorders.
Among the 13 studies testing lidocaine in Migraine Disorders, this one is the 9th largest by planned enrollment, is one of 3 that started in 2025, is one of 2 in phase 1, and was the 9th registered.
1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →5 of the 13 studies testing lidocaine in Migraine Disorders are open now, in 3 countries. Recruiting first, the newest first:
Daniel A Tonetti, MD · Sites in United States
Ages 18+
Mahidol University · Sites in Thailand
Ages 18–80
Cairo University · Sites in Egypt
Ages 18–65
Northwell Health · Sites in United States
Ages 18–75
By country, each count listing its studies:
Lidocaine: first FDA approval 1948 (XYLOCAINE), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 44 is below the median of 80 across 1,271 interventional studies indexed under Migraine Disorders.
Median enrollment 50 across the 13 interventional studies. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 10 most frequent:
Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
11 studies in Migraine Disorders by Assiut University: 8 open now, 8 under way, none of them phase 3.
Among the 11 studies in Migraine Disorders by Assiut University, this one is one of 2 that started in 2025, is the only one in phase 1, and was the 6th registered.
Assiut University’s Migraine Disorders studies by the year they started, since 2020.
2 of the studies testing lidocaine in Migraine Disorders that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06935552Assiut UniversityKetamine and Lidocaine Infusion in Refractory Chronic Migraine | 2026-11 |
| NCT07061847Northwell HealthBilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines | 2027-03-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies testing lidocaine in Migraine Disorders, from their registry updates:
Among Assiut University’s 11 in Migraine Disorders:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Ketamine and lidocaine infusion for refractory chronic migraine: Comparative Study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All participants must fulfill the following inclusion criteria
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
will receive ketamine
Drug: Ketamine infusion
will receive lidocaine
Drug: Lidocaine Intravenous Infusion
Drug: Dextrose 5% in water
group A will receive ketamine intravenous infusion
group B will receive lidocaine intravenous infusion
group C will only receive Dextrose 5% in water
Changes in pain scale using Numeric rating scale
Pain assessment by using a Numeric rating scale (0 (no pain) to 10 (worst possible pain). Scores of 1-3 are considered mild, 4-6 moderate, and 7-10 severe) before the infusion and daily for 1-week post infusion, then weekly for 6 weeks post infusion
Time frame: From enrollment to the end of treatment at 6 weeks
Changes in pain scale using Migraine disability assessment
Migraine disability assessment test before the infusion and daily for 1-week post infusion, then weekly for 6 weeks post infusion
Time frame: From enrollment to the end of treatment at 6 weeks
No study locations are listed for this record.
Plan to share: Undecided
Start is estimated for Jun 2025; primary completion for Nov 2026, 17 months later.
Of 53 phase 1 interventional studies under Migraine Disorders, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 19. This study's planned 17 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ketamine · Lidocaine